Magnesium Sulfate (Obstetric)
High-yield Verified · Oct 2026Magnesium prevents eclamptic seizures, and as a natural calcium antagonist it relaxes vessels and muscle — and, in excess, silences reflexes, breathing and the heart.
Nursing view → administration, monitoring and patient teaching
Compare: Labor drugs compared — uterotonics, tocolytics and magnesium sulfate →
Drugs
Mechanism
Acts as a physiologic calcium antagonist at the neuromuscular junction and in the CNS, reducing acetylcholine release and neuronal excitability — raising the seizure threshold (anticonvulsant) and relaxing smooth muscle (uterine tocolysis) and vasculature.
Preventing eclamptic seizures
Magnesium sulfate is the first-line treatment for preventing and controlling seizures in eclampsia, and it is labeled to prevent seizures in preeclampsia and control them in eclampsia. Although it is not an anticonvulsant and is not used for other seizure disorders, it works better for eclampsia than benzodiazepines or phenytoin, which are kept for patients who do not respond or cannot receive magnesium. It is continued for 24 hours after delivery or the last seizure.
Its exact mechanism is unclear. The label says magnesium prevents convulsions by blocking neuromuscular transmission and decreasing the acetylcholine released at the end plate. It is also thought to act as a vasodilator, protect the blood–brain barrier, reduce cerebral edema and act as a central anticonvulsant. Magnesium competes with calcium for voltage-dependent channels, and it is a voltage-dependent “plug” in the NMDA receptor, a major excitatory glutamate receptor.
One way out: the kidney
Magnesium is not metabolized. Only about 1–2% of total body magnesium is in the extracellular fluid, and about 30% of plasma magnesium is bound to albumin. It is excreted solely by the kidney, at a rate proportional to the serum concentration and the glomerular filtration rate.
So the label tells clinicians to use it with caution in renal impairment, where parenteral use may lead to magnesium intoxication; in severe renal insufficiency the dose is lower and serum levels are checked often. Acute kidney injury and chronic kidney disease are the major risk factors for magnesium toxicity. (Magnesium as an electrolyte is on the Electrolyte & Fluid Replacement page.)
In pregnancy: tocolysis, the fetus and the newborn
Magnesium has been described to inhibit calcium entry into uterine smooth muscle, but the label states that continuous magnesium sulfate for preterm labor is unapproved. Its fetal-harm warning: continuous use beyond 5–7 days can cause fetal hypocalcemia and bone abnormalities — skeletal demineralization, osteopenia and neonatal fractures. (Terbutaline and nifedipine tocolysis are on a later page.)
Given by continuous infusion, especially for more than 24 hours before delivery, magnesium can produce neuromuscular or respiratory depression in the newborn. Given within 24 hours of early preterm birth, it provides neuroprotection: it reduces the risk of cerebral palsy, and WHO strongly recommends it for women at risk of imminent preterm birth before 32 weeks.
Pharmacokinetics
- Onset and duration
- IV: anticonvulsant action is immediate and lasts about 30 minutes. IM: onset in about 1 hour, lasting 3–4 hours.
- Distribution
- About 1–2% of total body magnesium is in the extracellular fluid; plasma magnesium is about 30% albumin-bound.
- Metabolism
- Not metabolized.
- Excretion
- Solely by the kidney, in proportion to the serum concentration and the glomerular filtration rate.
Uses & drug choice
- Prevention & treatment of seizures in preeclampsia / eclampsia (first-line)
- Fetal neuroprotection — women at risk of imminent preterm birth before 32 weeks, to prevent cerebral palsy (WHO)
- Tocolysis — off-label: continuous use for preterm labor is unapproved (FDA label), and WHO notes other tocolytics have greater benefits
Adverse effects
- Flushing, sweating, hypotension
- Peripheral vasodilation: magnesium competes with calcium at vascular smooth-muscle channels and releases prostacyclin; low doses cause flushing and sweating, larger doses lower blood pressure.
- Loss of reflexes, respiratory paralysis
- Presynaptic calcium-channel block at the motor nerve terminal stops acetylcholine release.
- Somnolence and lethargy
- Enhanced NMDA-receptor block reduces excitatory neurotransmission.
- Heart block and cardiac arrest
- Competitive block of calcium channels in the sinoatrial and atrioventricular nodes, progressing to high-degree AV block.
- Maternal hypocalcemia with tetany
- Reported with magnesium sulfate therapy for eclampsia.
- Additive depression and excess neuromuscular block
- Additive CNS depression with barbiturates, opioids, hypnotics or anesthetics, and excessive block with neuromuscular blocking agents; in digitalized patients, calcium given for magnesium toxicity can cause serious conduction changes, including heart block.
Toxicity & antidote
As serum magnesium rises above about 4 mEq/L, the deep tendon reflexes first diminish and then disappear as levels approach 10 mEq/L, where respiratory paralysis may occur; heart block can occur at this or lower levels. The classic progression runs from flushing and nausea to areflexia, then respiratory depression and cardiac arrest. The mechanisms are calcium antagonism: blocked presynaptic calcium entry stops acetylcholine release (weakness, lost reflexes), vascular calcium-channel competition and prostacyclin release cause flushing and hypotension, and nodal calcium-channel block progresses to high-degree AV block and arrest.
Monitoring follows the same logic: the patellar reflex, the respiratory rate, urine output and serum levels; disappearance of the patellar reflex is a useful sign of early intoxication. Treatment is to stop the magnesium. IV calcium (calcium gluconate) antagonizes magnesium’s effects immediately but temporarily, so a calcium salt is kept immediately available and ventilation is supported until it is given; fluids, furosemide and hemodialysis increase magnesium removal.
Contraindications
- Significant renal impairment / oliguria use caution — Magnesium is cleared solely by the kidneys; poor output causes rapid accumulation to toxic, potentially fatal levels — use with caution, adjust dosing, and keep urine output at about 100 mL every 4 hours.
- Myasthenia gravis — In myasthenia gravis, neuromuscular function can worsen even at lower magnesium levels, so magnesium sulfate is contraindicated.
- Heart block or myocardial damage — Magnesium depresses cardiac conduction and can worsen block; parenteral magnesium sulfate is labeled as contraindicated here.
- IV magnesium in a mother with preeclampsia/eclampsia (‘toxemia of pregnancy’) during the 2 hours before delivery — premixed-bag label use caution — The premixed magnesium sulfate in water label lists this under its contraindications and gives no reason; the 50% vial label does not list it. Open RN, by contrast, describes magnesium for severe preeclampsia as typically started at the onset of labor and continued until 24 hours postpartum — so confirm the intrapartum magnesium plan with the provider as delivery nears.
High-yield
Practice questions
Q1A 24-year-old woman with preeclampsia with severe features is receiving a continuous magnesium sulfate infusion. Twelve hours later her patellar reflexes are absent, her respiratory rate is 9/min, and her urine output has fallen.
What is the most appropriate next step?
- A.Stop the infusion and give IV calcium gluconate
- B.Increase the infusion rate to prevent seizures
- C.Continue the infusion, because absent reflexes are the therapeutic target
- D.Continue the infusion and give furosemide alone
Show answer
A. Stop the infusion and give IV calcium gluconate — Disappearance of the patellar reflex is a sign of magnesium intoxication, and respiratory paralysis can follow as levels rise; falling urine output reduces magnesium’s only route of excretion. The magnesium is stopped and IV calcium gluconate given as the antidote, which antagonizes magnesium’s effects immediately but temporarily. Increasing or continuing the infusion worsens the toxicity, and furosemide only adds to removal once the magnesium has been stopped.
Q2A 29-year-old woman in preterm labor at 30 weeks has been kept on a continuous magnesium sulfate infusion for 9 days.
Which fetal risk does the label tie to this duration of use?
- A.An increased risk of cerebral palsy
- B.Respiratory depression in the newborn only after more than 2 weeks of infusion
- C.No fetal risk, because magnesium does not reach the fetus
- D.Fetal hypocalcemia and bone abnormalities such as demineralization and osteopenia
Show answer
D. Fetal hypocalcemia and bone abnormalities such as demineralization and osteopenia — The label warns that continuous administration beyond 5–7 days can cause fetal hypocalcemia and bone abnormalities, including skeletal demineralization, osteopenia and neonatal fractures, and that its use for preterm labor is unapproved. Magnesium reaches the fetus — newborns can show neuromuscular or respiratory depression after an infusion, especially one lasting more than 24 hours before delivery — and given within 24 hours of early preterm birth it reduces, rather than increases, the risk of cerebral palsy.
Q3A 32-year-old woman with myasthenia gravis develops preeclampsia with severe features at 35 weeks and needs seizure prophylaxis.
Which statement is correct?
- A.Magnesium sulfate is safe because it acts only in the brain
- B.Phenytoin is the preferred alternative
- C.Magnesium sulfate is contraindicated because neuromuscular function can worsen even at low concentrations
- D.Magnesium sulfate can be given with a neuromuscular blocking agent to prevent weakness
Show answer
C. Magnesium sulfate is contraindicated because neuromuscular function can worsen even at low concentrations — In myasthenia gravis, neuromuscular function can deteriorate even at lower magnesium concentrations, so magnesium sulfate is contraindicated; magnesium and phenytoin both cause muscle weakness that can lead to a myasthenic crisis, so levetiracetam or valproic acid is used instead. Magnesium blocks neuromuscular transmission by reducing acetylcholine release, and neuromuscular blocking agents add to that block rather than preventing weakness.
Q4A 27-year-old woman on a magnesium sulfate infusion for eclampsia needs an emergency cesarean delivery under general anesthesia. The plan includes an opioid, an induction agent and a neuromuscular blocking agent.
What is the main drug-interaction concern?
- A.Additive CNS depression and excessive neuromuscular block, so these drugs are dosed with caution
- B.Magnesium antagonizes neuromuscular blockers, so higher doses will be needed
- C.Magnesium shortens the effect of opioids
- D.There is no interaction, because magnesium acts only on the uterus
Show answer
A. Additive CNS depression and excessive neuromuscular block, so these drugs are dosed with caution — Magnesium has additive CNS depressant effects with opioids, hypnotics and anesthetics, so their doses are adjusted with caution, and excessive neuromuscular block has occurred when parenteral magnesium is given with a neuromuscular blocking agent. Magnesium itself blocks neuromuscular transmission, so it adds to these drugs rather than antagonizing or shortening them, and its actions extend well beyond the uterus.
Sources
- Eclampsia — magnesium sulfate as first-line seizure prophylaxis/treatment — StatPearls (NCBI)
- Magnesium Toxicity — reflex loss → respiratory depression → arrest; calcium antidote — StatPearls (NCBI)
- Diagnosis and Treatment of Eclampsia (J Cardiovasc Dev Dis 2024) — myasthenia gravis contraindication, eclampsia exam findings — MDPI (via PMC)
- Magnesium Sulfate in Water for Injection — FDA label (anticonvulsant levels, reflex/respiratory thresholds, preterm-labor use unapproved, fetal harm beyond 5–7 days) — DailyMed (U.S. National Library of Medicine)
- WHO Recommendations on Interventions to Improve Preterm Birth Outcomes (2015) — magnesium sulfate for fetal neuroprotection before 32 weeks — World Health Organization (NCBI Bookshelf)
- WHO recommendation on tocolytic therapy for improving preterm birth outcomes (2022) — World Health Organization (NCBI Bookshelf)
- Hypermagnesemia — StatPearls (eclampsia stop rules; levels and cardiorespiratory arrest) — StatPearls (NCBI Bookshelf)
- Magnesium Sulfate — StatPearls (therapeutic and toxic serum levels in preeclampsia/eclampsia) — StatPearls (NCBI Bookshelf)
- Magnesium Sulfate Injection 50% — contraindications, safe-dose monitoring (FDA label) — DailyMed (NLM)
- Labor & Delivery Care — minimizing environmental stimuli in preeclampsia (Nursing Health Promotion) — Open RN (NCBI Bookshelf)
- High-Risk Perinatal Client Care — magnesium sulfate nursing care (Nursing Health Promotion) — Open RN (NCBI Bookshelf)
- Preterm Labor — magnesium sulfate for fetal neuroprotection — StatPearls (NCBI)
- Tocolysis — magnesium and uterine calcium entry — StatPearls (NCBI)
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.